Featured

Margin debt has risen to a record $1.5 trillion, with borrowing rising far faster than stock prices. The rally may continue, but history suggests that excessive leverage tends to turn rapidly into a market downfall.

Record-breaking funding rounds for Anthropic and OpenAI mark a new phase in the AI race. With vast sums flowing into compute and scale, the battle is no longer about ideas, but about who can afford to build intelligence first.

AI driven layoffs and immigration crackdowns are hitting the labor market at once. As white- and blue-collar jobs disappear, weakening consumer confidence threatens the spending that underpins the American economy.

Post-pandemic shifts have broken the traditional real-estate cycle. Demand is no longer rebounding evenly, but concentrating in top-tier spaces, leaving weaker offices behind and forcing cities to rethink how to repurpose surplus supply.

Hapag-Lloyd’s $4.2bn bid for ZIM highlights shipping’s relentless drive for scale. The deal promises stronger routes and cost synergies, but political tensions, falling revenues, and national-security concerns make its payoff far from certain.

Citigroup’s planned divestment of Banamex reveals a stark valuation gap, with offers far below peers. A future IPO may recover value, but weak market depth, regulatory overhang and investor skepticism make the outcome far from certain.

Quantinuum’s looming IPO tests whether quantum computing is nearing commercial reality. With fault-tolerant breakthroughs, rising revenue, and bold valuations, the company could define the industry’s next decade, if qubits scale fast enough to justify investor faith.

Margin debt has risen to a record $1.5 trillion, with borrowing rising far faster than stock prices. The rally may continue, but history suggests that excessive leverage tends to turn rapidly into a market downfall.

Post-pandemic shifts have broken the traditional real-estate cycle. Demand is no longer rebounding evenly, but concentrating in top-tier spaces, leaving weaker offices behind and forcing cities to rethink how to repurpose surplus supply.

Citigroup’s planned divestment of Banamex reveals a stark valuation gap, with offers far below peers. A future IPO may recover value, but weak market depth, regulatory overhang and investor skepticism make the outcome far from certain.

Old Glory Bank is wagering its century-old charter on crypto, pursuing a $250 million SPAC merger to fuse FDIC-insured banking with stablecoins, instant on-off ramps, and youth-driven digital demand—while balancing strict regulation against its promise of financial autonomy.

Once dismissed as speculative shortcuts, SPACs have evolved into a legitimate financing tool, especially for early-stage biotech. SL Bio’s $5.7B SPAC merger highlights why firms with long timelines and uncertain revenue may trade dilution and misaligned incentives for speed, certainty, and survival.

The rush toward AI infrastructure and electrification has turned critical minerals into one of the most crowded trades of 2026. EMAT’s decision to enter public markets through a reverse merger offers speed and exposure, but little of the trust traditionally built through an IPO.

In a single year, Qualcomm completed six acquisitions across AI and semiconductor infrastructure. The message is clear: as its traditional modem business faces long-term erosion, Qualcomm is racing to transform itself from a communications specialist into a fully integrated AI platform company.

Leveraged buyouts thrive on predictability. Video games do not. EA’s $55 billion take-private deal forces one of the most creatively volatile industries to operate under one of the most financially rigid ownership structures.

Johnson & Johnson dropped $14.6 billion on a company whose value rests almost entirely on one psychiatric drug. Caplyta may be a blockbuster, or it may be the most expensive overreach in biotech since 2022. This is a high-risk, high-premium gamble at a moment when Big Pharma can’t afford missteps.